R21/Matrix-M

BIOLOGICAL2 trials

Sponsors

University of Oxford

Conditions

MalariaMalaria,Falciparum

Phase 2

A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults

TerminatedNCT03947190

University of OxfordMalaria,Falciparum

Start: 2022-08-31End: 2023-02-26Updated: 2025-02-20

Phase 3

R21/Matrix-M in African Children Against Clinical Malaria

Active, not recruitingNCT04704830

University of OxfordMalaria

Start: 2021-04-29End: 2028-04-01Target: 4800Updated: 2026-02-23

Related Papers

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.

2026-01-06

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.

2024-02-01216 citations